{"id":34010,"date":"2023-03-07T14:04:06","date_gmt":"2023-03-07T09:04:06","guid":{"rendered":"http:\/\/myanmarnewsgazette.com\/?guid=a6263af7efb31a08143370cea154300a"},"modified":"2023-03-07T14:04:06","modified_gmt":"2023-03-07T09:04:06","slug":"jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/","title":{"rendered":"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders"},"content":{"rendered":"<p align=\"center\"><strong>Jeito Capital <\/strong><strong>co-leads <\/strong><strong>a <\/strong><strong>EUR<\/strong><strong> 1<\/strong><strong>04<\/strong><strong> million <\/strong><strong>f<\/strong><strong>inancing in<\/strong> <strong>Noema Pharma<\/strong><strong>, <\/strong><br \/>\n<strong>a clinical-stage biopharma company<\/strong> <strong>targeting <\/strong><br \/>\n<strong>debilitating <\/strong><strong>central nervous system<\/strong><strong> disorders<\/strong><\/p>\n<ul type=\"disc\">\n<li><em>Noema Pharma&#8217;s clinical-stage assets and diversified pipeline <\/em><em>hold<\/em> <em>significant potential <\/em><em>in developing<\/em><em> effective <\/em><em>therapeutic options for patients with debilitating <\/em><em>central nervous system (<\/em><em>CNS<\/em><em>)<\/em><em> disorders, <\/em><em>addressing <\/em><em>high unmet medical need<\/em><em>s<\/em><\/li>\n<li><em>Jeito Capital&#8217;s <\/em><em>investment in Noema Pharma marks its <\/em><em>second<\/em><em> in <\/em><em>the field of<\/em> <em>n<\/em><em>eurological disorders <\/em><em>and represents a significant opportunity to support <\/em><em>this <\/em><em> promising therapeutic area with high growth potential<\/em><\/li>\n<li><em>Through <\/em><em>its investment<\/em><em>, Jeito Capital<\/em> <em>aims to promote <\/em> <em>the <\/em><em>expansion and acceleration <\/em><em>of <\/em><em>Noema\u2019s <\/em><em>development <\/em><em>activit<\/em><em>ies<\/em><em> and<\/em> <em>bolster<\/em> <em>value<\/em><em> creation<\/em><em> in France<\/em><em> and in Europe<\/em><em>,<\/em> <em>reinforcing<\/em><em> its dedication to fostering the growth of biopharmaceutical champions in the region<\/em><\/li>\n<\/ul>\n<p style=\"text-align: left;\" align=\"justify\"><strong>Paris, France<\/strong><strong>, <\/strong><strong>March <\/strong><strong>7<\/strong><sup><strong>th<\/strong><\/sup> <strong>202<\/strong><strong>3<\/strong> &#8211; Jeito Capital (&#8220;Jeito&#8221;), the largest fully independent private equity firm dedicated to healthcare and biopharma in Europe, announced today that it has co-led a EUR 104 million (CHF 103 million, approx. USD 112 million) financing in Noema Pharma (the \u201cCompany\u201d), a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders. Noema Pharma has offices in Switzerland, France, and in the US.<\/p>\n<p style=\"text-align: left;\" align=\"justify\">The oversubscribed financing was co-led by Jeito and Forbion with participation from new investors such as the UPMC Enterprises joined by existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus.<\/p>\n<p style=\"text-align: left;\" align=\"justify\">Founded in 2019 in Paris, France, Noema Pharma currently has multiple active Phase 2b clinical trials in highly undertreated CNS conditions including seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has also completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended to adolescents. As part of its indication expansion strategy, the Company also anticipates initiating clinical development in Atypical Depression and Binge Eating Disorders.<\/p>\n<p style=\"text-align: left;\" align=\"justify\">Proceeds from the financing will primarily be used to advance the Company\u2019s clinical-stage assets.<\/p>\n<p style=\"text-align: left;\" align=\"justify\">Jeito selected Noema Pharma in line with its investment strategy of supporting the development of the most promising European biopharma companies with high growth and acceleration potential. As Jeito\u2019s second investment in a biopharma company targeting neurological diseases, Noema Pharma&#8217;s maturing clinical-stage pipeline shows great promise for helping patients who currently lack effective treatments or face unmet medical needs.<\/p>\n<p style=\"text-align: left;\" align=\"justify\">In addition, Jeito will invest in Noema Pharma SAS (France), enabling it to expand its clinical trials and safety monitoring efforts in France and in Europe. This is expected to create new job opportunities and provide support for French and European suppliers in the manufacturing process. Rachel Mears, Partner at Jeito Capital, will join Noema Pharma\u2019s Board of Directors.<\/p>\n<p style=\"text-align: left;\" align=\"justify\"><strong>Dr Rafa\u00e8le Tordjman, MD, PhD, Founder and CEO of Jeito Capital, commented<\/strong> <em>&#8220;We are excited to partner with Noema Pharma in their mission to <\/em><em>accelerate the <\/em><em>develop<\/em><em>ment of<\/em><em> innovative treatments for debilitating CNS disorders. <\/em><em>I am particularly proud that the company born in Paris <\/em><em>three<\/em><em> years ago<\/em><em>,<\/em><em> which developed in Switzerland<\/em><em> and the US<\/em><em>,<\/em> <em>continues<\/em><em> to create value in <\/em><em>France and <\/em><em>Europe<\/em><em>. <\/em><em>This reflects Jeito Capital&#8217;s strong commitment to fostering the emergence of potential global biopharma leaders from Europe<\/em><em>.<\/em> <em>As Jeito Capital&#8217;s <\/em><em>second<\/em><em> investment in a <\/em><em>neurology<\/em><em> company<\/em><em>, <\/em><em>Noema Pharma<\/em><em> with it<\/em><em>s clinical-stage assets and diversified pipeline <\/em><em>has<\/em> <em>shown significant potential for the development of effective<\/em><em> innovative<\/em> <em>therapies<\/em> <em>for the benefit of patients<\/em><em>.&#8221;<\/em><\/p>\n<p style=\"text-align: left;\" align=\"justify\"><strong>Rachel Mears, Partner at Jeito Capital<\/strong> <strong>added<\/strong><em>: <\/em><em>\u201c<\/em><em>One of the pillars of our investment strategy is to deploy capital in truly differentiated and innovative therapies with high unmet medical need<\/em><em>. <\/em><em>The clinical work being undertaken by Noema Pharma fit these criteria exactly. The <\/em><em>expertise, quality and <\/em><em>dedication of the Noema team <\/em><em>are<\/em><em> clear to see<\/em><em> in their development work<\/em><em> and positio<\/em><em>n<\/em><em> the <\/em><em>C<\/em><em>ompany as <\/em><em>an<\/em><em> upcoming global <\/em><em>CNS <\/em><em>leader. We are excited to partner with Noema Pharma to accelerate <\/em><em>its<\/em><em> mission of developing effective solutions for patients <\/em><em>with<\/em><em> CNS disorders and are committed to supporting their continued growth and success.&#8221;<\/em><\/p>\n<p style=\"text-align: left;\" align=\"justify\"><strong>Luigi Costa, Chief Executive Officer of Noema Pharma said:<\/strong> <em>\u201c<\/em><em>We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. We welcome our new investors who bring extensive expertise and knowledge of drug development and company building and add further strength to our robust investor base. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.<\/em><em>\u201d<\/em><\/p>\n<p style=\"text-align: left;\" align=\"justify\"><strong>About Jeito Capital<\/strong><\/p>\n<p style=\"text-align: left;\">Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients\u2019 access globally, especially in Europe and the United States. Jeito Capital has \u20ac534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.<\/p>\n<p style=\"text-align: left;\" align=\"justify\"><a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DRSv-7K4114EUZxvXH5ajRzFydHgoMjojUqqIvp3sga9hW0TGX9QK41GdcqOkRTklhhaRfdA4DXOn07kR3rq-xcsvGbLSx1RG8IM4RpmYI3g%3D&amp;source=gmail-html&amp;ust=1678266107387000&amp;usg=AOvVaw2q_6s8h_31ucetPJL5L0iG\"  rel=\"nofollow noopener noreferrer\"><u>@Jeito_life<\/u><\/a><a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3D23fFBys2RL2GFix4yPTWfICuQiRdwTZEgjwV4c3K6YHsxyAYLbr3ijf-rh3S8YeKBOShGw2TC4Z025uo3t-R23M5k5IX1HAojxTHwuoCIkmK9o54UjdeghCXL8LM-kr1xZxtOFQGNIzD1SQam0Qatw%3D%3D&amp;source=gmail-html&amp;ust=1678266107387000&amp;usg=AOvVaw2Ag4e-3OwEV1KEYCah8jpB\"  rel=\"nofollow noopener noreferrer\"><u>LinkedIn<\/u><\/a>For more information, please visit www.jeito.life, or follow <a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DRSv-7K4114EUZxvXH5ajR0XYa-6uKJXfB3jObfJrG671jxPJz5x5mX1rdMrZ6LRRu_yQLtp_gMS09gxQQl__0g3KR_FoOYT2KFwoDXylQ8k%3D&amp;source=gmail-html&amp;ust=1678266107387000&amp;usg=AOvVaw30l20Zq_SzNYls6K6WaBRK\"  rel=\"nofollow noopener noreferrer\"><u>@Jeito_life<\/u><\/a> on Twitter or <a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3D23fFBys2RL2GFix4yPTWfFQIvGWy98f8EtNKw3uilQ0Up9T2wBYbYFAClBPx4QREdzpFgeuM8YScN4ZxTBLEiHC71E_Blg1_QlwYlrgfxt4dVlu7-x42xzH_WLmPwBFsAvhRRG8Q6xYtbMoTVH0jtQ%3D%3D&amp;source=gmail-html&amp;ust=1678266107387000&amp;usg=AOvVaw2iGg0qpKn1WryZETEzFLUZ\"  rel=\"nofollow noopener noreferrer\"><u>LinkedIn<\/u><\/a>.<br \/>\n<strong>About Noema Pharma<\/strong><\/p>\n<p style=\"text-align: left;\" align=\"justify\">Noema Pharma (<a href=\"https:\/\/www.google.com\/url?q=http:\/\/www.noemapharma.com&amp;source=gmail-html&amp;ust=1678266107387000&amp;usg=AOvVaw1So5fASoZFjj1mnAVt3bFK\"  rel=\"noopener noreferrer\">www.noemapharma.com<\/a>) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.<\/p>\n<p style=\"text-align: left;\" align=\"justify\"><strong>For further information please <\/strong><strong>contact:<\/strong><\/p>\n<p style=\"text-align: left;\"><strong>Jeito Capital<\/strong><br \/>\nRafa\u00e8le Tordjman, Founder &amp; CEO<br \/>\nAssia Mouhout, EA<br \/>\nTel : +33 6 76 49 37 94<\/p>\n<p style=\"text-align: left;\"><strong>Consilium Strategic Communications <\/strong>Mary-Jane Elliott \/ Davide Salvi \/ Kris Lam<br \/>\n<a href=\"mailto:Jeito@consilium-comms.com\"  rel=\"noopener noreferrer\">Jeito@consilium-comms.com<\/a><br \/>\nTel: +44 (0) 20 3709 5700<\/p>\n<p style=\"text-align: left;\">Marion Bougeard<br \/>\n<a href=\"mailto:marion@achto-conseil.fr\"  rel=\"noopener noreferrer\">marion@achto-conseil.fr<\/a><br \/>\nTel : +33 6 76 73 57 31<\/p>\n<p align=\"center\">GlobeNewswire Distribution ID 1000796612<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders Noema Pharma\u2019s clinical-stage assets and diversified pipeline hold significant potential in developing effective therapeutic options for patients with debilitating central nervous system (CNS) disorders, addressing high unmet medical needs Jeito Capital\u2019s investment in Noema [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders - Myanmar News Gazette<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders - Myanmar News Gazette\" \/>\n<meta property=\"og:description\" content=\"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders Noema Pharma\u2019s clinical-stage assets and diversified pipeline hold significant potential in developing effective therapeutic options for patients with debilitating central nervous system (CNS) disorders, addressing high unmet medical needs Jeito Capital\u2019s investment in Noema [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/\" \/>\n<meta property=\"og:site_name\" content=\"Myanmar News Gazette\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-07T09:04:06+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f\"},\"headline\":\"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders\",\"datePublished\":\"2023-03-07T09:04:06+00:00\",\"dateModified\":\"2023-03-07T09:04:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/\"},\"wordCount\":1073,\"publisher\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\"},\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/\",\"url\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/\",\"name\":\"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders - Myanmar News Gazette\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#website\"},\"datePublished\":\"2023-03-07T09:04:06+00:00\",\"dateModified\":\"2023-03-07T09:04:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/myanmarnewsgazette.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#website\",\"url\":\"https:\/\/myanmarnewsgazette.com\/\",\"name\":\"Myanmar News Gazette\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/myanmarnewsgazette.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\",\"name\":\"Myanmar News Gazette\",\"url\":\"https:\/\/myanmarnewsgazette.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png\",\"contentUrl\":\"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png\",\"width\":200,\"height\":200,\"caption\":\"Myanmar News Gazette\"},\"image\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/myanmarnewsgazette.com\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders - Myanmar News Gazette","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/","og_locale":"en_US","og_type":"article","og_title":"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders - Myanmar News Gazette","og_description":"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders Noema Pharma\u2019s clinical-stage assets and diversified pipeline hold significant potential in developing effective therapeutic options for patients with debilitating central nervous system (CNS) disorders, addressing high unmet medical needs Jeito Capital\u2019s investment in Noema [\u2026]","og_url":"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/","og_site_name":"Myanmar News Gazette","article_published_time":"2023-03-07T09:04:06+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/#article","isPartOf":{"@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/"},"author":{"name":"admin","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f"},"headline":"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders","datePublished":"2023-03-07T09:04:06+00:00","dateModified":"2023-03-07T09:04:06+00:00","mainEntityOfPage":{"@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/"},"wordCount":1073,"publisher":{"@id":"https:\/\/myanmarnewsgazette.com\/#organization"},"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/","url":"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/","name":"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders - Myanmar News Gazette","isPartOf":{"@id":"https:\/\/myanmarnewsgazette.com\/#website"},"datePublished":"2023-03-07T09:04:06+00:00","dateModified":"2023-03-07T09:04:06+00:00","breadcrumb":{"@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-co-leads-a-eur-104-million-financing-in-noema-pharma-a-clinical-stage-biopharma-company-targeting-debilitating-central-nervous-system-disorders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/myanmarnewsgazette.com\/"},{"@type":"ListItem","position":2,"name":"Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders"}]},{"@type":"WebSite","@id":"https:\/\/myanmarnewsgazette.com\/#website","url":"https:\/\/myanmarnewsgazette.com\/","name":"Myanmar News Gazette","description":"","publisher":{"@id":"https:\/\/myanmarnewsgazette.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/myanmarnewsgazette.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/myanmarnewsgazette.com\/#organization","name":"Myanmar News Gazette","url":"https:\/\/myanmarnewsgazette.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/","url":"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png","contentUrl":"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png","width":200,"height":200,"caption":"Myanmar News Gazette"},"image":{"@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/myanmarnewsgazette.com\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts\/34010"}],"collection":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/comments?post=34010"}],"version-history":[{"count":0,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts\/34010\/revisions"}],"wp:attachment":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/media?parent=34010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/categories?post=34010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/tags?post=34010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}